A clinical trial of a drug used for treating lung cancer has revealed “a remarkable advancement”.
As per the trial, the new anti-cancer drug has unveiled that 60% of patients are still alive. Moreover, the cancer did not spread to any other part of the body, according to Interesting Engineering.
The protein anaplastic lymphoma kinase (ALK) plays a prominent role in regulating cell growth. It is produced as a result of the ALK gene. This gene can be rearranged in certain cancers including non-small cell lung cancer (NSCLC).
Among these, ALK-positive tumors occur in approximately 3% to 5% of cases among these cancers.
The trial’s results revealed that Lorlatinib is a third-generation ALK inhibitor. Used as the standard first-line treatment for patients with ALK-positive NSCLC, it is the latest in a class of drugs.
Led by the Peter MacCallum Cancer Center in Melbourne, Australia, a recent international clinical trial evaluated the drug’s impact on long-term disease progression in patients with advanced ALK-positive NSCLC.
Peter Mac’s Professor Ben Solomon, the study’s lead and corresponding author, said in an interview with The Guardian: “To our knowledge, these results are unprecedented.”
New case reported in 27-month-old child in KP's DI Khan
Govt says it is aimed at creating Britain's first "smoke-free generation"
Health experts warn that HIV is far from from being stamped out and more needs to be done
Experts say that single largest reason behind egg scarcity is bird flu
Warnings include depictions of feet with amputated toes, along with written descriptions of health risks
"I'm so grateful to doctors, nurses here for giving me hope," says 57-year-old patient Cheryl Mehrkar
